Splash invests C$300,000 in Avicanna to advance healthcare shift
Splash Beverage Group, Inc. completed a CDN$300,000 strategic investment in Avicanna Inc., acquiring 2,000,000 common shares and 1,000,000 warrants via a non-brokered private placement on June 9, 2026. This move supports Splash's transformation into a cannabinoid-focused healthcare platform, leveraging Avicanna's clinical research, pharmaceutical portfolio, and debt-free balance sheet.
*this image is generated using AI for illustrative purposes only.
Splash Beverage Group, Inc. (NYSE: SBEV) has completed a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products. The investment, finalized on June 9, 2026, involved the acquisition of 2,000,000 common shares and 1,000,000 warrants through a non-brokered private placement. This capital allocation aligns with Splash's previously announced transformation into a cannabinoid health, wellness, and healthcare-focused platform company.
The company views Avicanna as a sophisticated platform positioned for the evolution of the medical cannabinoid market in the United States. "Avicanna has spent years building many of the capabilities we believe will define the future of cannabinoid medicine," said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group. He cited Avicanna's intellectual property, product portfolio, clinical development, and operational execution as key differentiators.
Strategic Attributes of Avicanna
Splash's investment thesis is supported by several attributes that distinguish Avicanna within the cannabinoid sector:
- One of North America's leading cannabinoid-based biopharmaceutical companies with proprietary formulations and clinical-stage pharmaceutical assets.
- A commercial-stage pharmaceutical portfolio that includes Trunerox™, an approved cannabidiol treatment for severe epilepsy indications.
- MyMedi.ca, a medical cannabis care platform providing pharmacist-led patient care and reimbursement support.
- Real-world operating experience within Canada's federally regulated medical cannabis system.
- A vertically integrated international platform with pharmaceutical-grade manufacturing in Colombia.
- An experienced management team with deep expertise across healthcare and pharmaceuticals.
- A debt-free balance sheet.
Investment Details
The following table outlines the specifics of the transaction:
| Investment Component | Details |
|---|---|
| Total Investment | CDN$300,000 |
| Common Shares Acquired | 2,000,000 |
| Warrants Acquired | 1,000,000 |
| Transaction Type | Non-brokered private placement |
| Completion Date | June 9, 2026 |
Management believes the long-term cannabinoid opportunity will be defined by clinical evidence, physician participation, and regulatory compliance. Cobb noted that Avicanna operates within a federally regulated framework that incorporates characteristics increasingly evaluated in the U.S. healthcare system. Splash views this investment as a strategic allocation into a company suited for the next phase of cannabinoid medicine.
How will Splash Beverage Group leverage Avicanna's pharmaceutical assets to accelerate its own transition into the healthcare sector?
What specific regulatory milestones in the U.S. market are required to validate this investment thesis?
Does this strategic allocation signal a potential shift in Splash's capital expenditure away from its traditional beverage segments?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
